Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar 30;388(1-2):202-8.
doi: 10.1016/j.ijpharm.2010.01.013. Epub 2010 Jan 18.

Nasal absorption of mixtures of fast-acting and long-acting insulins

Dennis J Pillion  1 , Michael D Fyrberg, Elias Meezan
Affiliations

Nasal absorption of mixtures of fast-acting and long-acting insulins

Dennis J Pillion et al. Int J Pharm. .

Abstract

Mixtures of fast-acting and long-acting insulins were administered nasally to anesthetized, hyperglycemic rats in the presence and absence of tetradecyl-beta-d-maltoside (TDM). The fast-acting analogs, aspart insulin, lispro insulin and glulisine insulin, were all rapidly absorbed from the nose when applied individually with 0.125% TDM (T(max)=15min). One long-acting insulin analog, glargine insulin, was also absorbed from the nose when applied individually in the presence of 0.125% TDM (T(max)=60min). The other long-acting insulin analog, detemir insulin, was not soluble when formulated with 0.125% TDM. A series of mixtures (1:1) of the three rapid-acting insulins and long-acting glargine insulin were formulated with 0.125% TDM and applied nasally. The pharmacokinetic and pharmacodynamic profiles of the insulin mixtures reflected the additive contributions of both the rapid-acting and the long-acting insulins. These results support the possibility of formulating certain insulin mixtures in tandem to provide nasal insulin products that match the needs of patients with diabetes mellitus better than those currently available.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Plasma insulin levels in rats that received 2 units of various fast-acting insulins (A) or regular or long-acting insulins (B) with or without 0.125% TDM. Each data point represents the mean +/- SEM of 3-6 animals.
Figure 1
Figure 1
Plasma insulin levels in rats that received 2 units of various fast-acting insulins (A) or regular or long-acting insulins (B) with or without 0.125% TDM. Each data point represents the mean +/- SEM of 3-6 animals.
Figure 2
Figure 2
Blood glucose levels in rats that received 2 units of various fast acting insulins (A) or regular or long-acting insulins (B) with or without 0.125% TDM. Each data point represents the mean +/- SEM of 3-6 animals.
Figure 2
Figure 2
Blood glucose levels in rats that received 2 units of various fast acting insulins (A) or regular or long-acting insulins (B) with or without 0.125% TDM. Each data point represents the mean +/- SEM of 3-6 animals.
Figure 3
Figure 3
Plasma insulin levels in rats that received 2 units of various insulins 15 minutes after the administration of 0% or 0.125% TDM. Each data point represents the mean +/-SEM of 3-6 animals.
Figure 4
Figure 4
Blood glucose levels in rats that received 2 units of various insulins 15 minutes after the administration of 0% or 0.125% TDM. Each data point represents the mean +/- SEM of 3-6 animals.
Figure 5
Figure 5
Plasma insulin levels in rats that received 2 units of a mixed insulin formulation with 0.125% TDM. Each data point represents the mean +/- SEM of 3-6 animals.
Figure 6
Figure 6
Blood glucose levels in rats that received 2 units of a mixed insulin formulation with 0.125% TDM. Each data point represents the mean +/- SEM of 3-6 animals.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ahsan F, Arnold JJ, Yang T, Meezan E, Schwiebert EM, Pillion DJ. Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-B-cyclodextrin, on insulin movement across human bronchial epithelial cells 16HBE 14o. Eur J Pharm Sci. 2003;20:27–34. - PubMed
    1. Arnold JJ. Doctoral Dissertation. University of Alabama at Birmingham; 2004. Systemic Delivery of Peptides and Macromolecules in Nasal Formulations Containing an Alkylglycoside.
    1. Arnold JJ, Ahsan F, Meezan E, Pillion DJ. Nasal administration of low molecular weight heparin. J Pharm Sci. 2002;91(7):1707–14. - PubMed
    1. Arnold JJ, Ahsan F, Meezan E, Pillion DJ. Correlation of tetradecylmaltoside induced increase in nasal peptide drug delivery with morphological changes in nasal epithelial cells. J Pharmaceut Sci. 2004;93:2205–2213. - PubMed
    1. Arnold JJ, Fyrberg MD, Meezan E, Pillion DJ. Reestablishment of the Nasal Permeability Barrier to Several Peptides Following Exposure to the Absorption Enhancer Tetradecyl-β-D-Maltoside. J Pharmaceut Sci. 2009 in press. - PubMed

Publication types